Paige Introduces Multi-Modal AI for Enhanced Precision Oncology and Drug Discovery

by Roman Kasianov       News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   422    Comments
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

Paige, a provider of digital pathology solutions and AI applications, has launched a new service line leveraging its Foundation Models. These models include a large multi-modal AI model in pathology and oncology. The new service is intended to assist AI developers, computational pathology product creators, and life sciences companies in developing AI models for applications such as research and development, clinical trials, and commercial needs. The initiative aims to contribute to advancements in precision oncology, with the goal of improving cancer diagnosis and treatment.

Image credit: Paige

Paige’s Foundation Models offer a distinct approach compared to traditional AI development methods. Conventional methods often require specific models to be trained for individual tasks using specific data, a process that is both time-consuming and resource-intensive. Paige’s models, however, can be adapted to a wide range of tasks without the need for individual training on each task. This flexibility has the potential to reduce the time and computational resources needed and lower the data requirements for developing advanced AI systems.

See also: The Growing Momentum for AI Foundation Models in Biotech and 12 Notable Companies

The new service line provides access to advanced pre-trained models, including updated versions of Virchow, described as the largest image-based AI model aimed at addressing cancer, and the newly released PRISM Foundation Model. PRISM, a multi-modal slide-level model, is designed to enhance reporting and generative capabilities, offering analytical data for multi-tissue and rare cancer detection, rare biomarker identification, cellular subtyping, spatial biology, and therapy response prediction. This specificity and accuracy were, reportedly, not previously accessible with older technologies.

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments